Jinzhe Biotech Secures Pre-A Funding to Advance tPBM-Based Brain Health Solutions

Recently, FITFOCUS (hereinafter referred to as "FITFOCUS") announced the completion of its Pre-A round of financing.This round of financing was exclusively invested by Yuanming Capital, a well-known investment institution in the healthcare field., and the funds raised will be used to accelerate the clinical progress and registration approval of its core product, a wearable transcranial photobiomodulation therapy device for sleep disorders and other related products.

As a leading enterprise in China focusing on improving mitochondrial dysfunction, FITFOCUS relies on a multidisciplinary team combining medicine, engineering, and research,Successfully built a dual-driven model of multimodal monitoring + transcranial photobiomodulation (tPBM), and to build a new paradigm for brain disease and brain health solutions.

Around sleep disorders and diseases such as anxiety and depressionRecently, FITFOCUS has laid out EEG-tPBM for closed-loop neuromodulation.Around Neurodegenerative DiseasesThe company has developed two oligomer products that are the first in China to enable precise detection and dynamic reflection of disease progression. These products support convenient fingertip blood sampling, offer superior performance at a low cost, and can be combined with a lightweight, non-invasive tPBM head-worn device for the intervention and treatment of MCI and early AD. This dual-driven model is expected to fill the gap in solutions for brain diseases in China.

With a new round of funding, the company's core product development process will accelerate further, reshaping the landscape of the brain health disease diagnosis and treatment industry.

Mitochondrial energy metabolism imbalance, failure of oxidative stress regulation, and calcium homeostasis disorders are gradually becoming important multi-pathway therapeutic targets for central nervous and psychiatric system diseases.

tPBM, as a novel physical neuromodulation method, demonstrates its technical advantages in three dimensions:

1. Compared with traditional physical regulation methods such as transcranial magnetic stimulation (TMS) and transcranial electrical stimulation (TES), it can achieve excitatory or inhibitory regulation of brain regions.

2. Target area modulation at different depths can be achieved through direct penetration or region-to-region regulation.

3. Based on the improvement of mitochondrial dysfunction as a multi-target effect, the pharmacological characteristics of "electronic drugs" can be achieved.

In 2021, Cognito Therapeutics, a company associated with MIT, received FDA Breakthrough Device Designation for its 40Hz transocular photobiomodulation (PBM) therapy, demonstrating its promising potential to improve cognition in AD patients through neural oscillations. The company has raised over $250 million to accelerate the development of its PBM pipeline. As another specialized technology track within the broader PBM category, tPBM exhibits unique potential for deeper exploration and is expected to address a wider range of brain health conditions beyond current cognitive categories.

Danyang Huichuang is also making significant investments in the near-infrared phototherapy field, securing nearly 100 million RMB in funding in 2024 to advance the clinical progress of tPBM in the AD field. FITFOCUS continues to focus on key technical challenges such as beam energy consistency and brain region modulation, achieving improvements in multiple critical dimensions including light uniformity, irradiation depth, and penetration efficiency. The company has currently established R&D pipelines for various brain disorders such as migraines, sleep disorders, AD, Parkinson's disease, and depression, with three IIT clinical trials currently underway.

The productization of tPBM technology requires a multidisciplinary approach and the concept of precision medicine to achieve technological breakthroughs in the field of brain disease treatment and build a differentiated product pipeline. Therefore, a deeply integrated interdisciplinary team structure that spans the entire technology chain is essential for collaboration.

The founding team of the company brings together talents from fields such as biological protein engineering, brain science neural modulation, clinical medicine, optoelectronic physics, and algorithms, forming a "medical-engineering-research" integrated innovative model. Core team members include senior experts with experience in biomedical research and industry, scientific talents with rich experience in brain science research and management who lead several national key projects, and optics and engineering experts deeply engaged in optical and engineering research at the product level. Through close interdisciplinary collaboration, the team has successfully transformed cutting-edge brain science technologies.

Notably, FITFOCUS has also established an innovative consortium characterized by "top talents + top resources" through the establishment of a think tank network led by academicians and closed-loop validation from authoritative medical institutions. While ensuring the strategic height of the technical direction, it bridges the last mile from the laboratory to the bedside.

At the basic research end, a scientific advisory team composed of academicians from the two academies and industry experts provides top-level technical guidance for FITFOCUS's technology development. In the technology implementation phase, FITFOCUS collaborates clinically with institutions such as the First Medical Center of the Chinese People's Liberation Army General Hospital and Beijing Tiantan Hospital affiliated with Capital Medical University to create products with clinical value.

In view of the current development of innovative medical devices at home and abroad, FITFOCUS is undoubtedly on the right path.

Looking overseas, Stanford University's Biodesign innovation model is precisely based on the close connection of medicine, engineering, industry, academia, and research to accurately identify clinical needs, efficiently develop solutions, and achieve commercial implementation. When clinical institutions, research organizations, innovative enterprises, and capital are effectively "linked," the current of innovation forms an invisible magnetic field, driving the industry to generate more valuable innovations. FITFOCUS, with interdisciplinary collaboration at its core, has built a full-chain innovation system of "basic research-clinical validation-industrial implementation," effectively solving the problem of disconnection between laboratory results and clinical needs. This has led to numerous cutting-edge technological innovations and improved the transformation and implementation efficiency of advanced brain disease treatment technologies.

At present, brain-computer interfaces are entering a stage of explosive growth.

According to forecasts by VCBeat, the global brain-computer interface market size will exceed $6 billion by 2028, with a five-year compound annual growth rate of 25.22%. Although China started relatively late, it has received significant policy support. Not only did the Ministry of Industry and Information Technology list it as one of the "Top Ten Iconic Future Industries" in 2024, but in March this year, the National Healthcare Security Administration also established a separate service price program for brain-computer interface technology, providing substantial support for the commercialization of innovative brain science technologies.

FITFOCUS has become a core member unit of the Brain-Computer Interface Industry Alliance and initiated the Brain Science Special Fund under the Zhongguan Village Precision Medicine Foundation. These actions not only confirm the market recognition of its technical roadmap but also highlight the strategic value of the company’s full-chain innovation system in the brain science track, encompassing "basic research-clinical validation-industrial implementation." With continuous release of industry policy benefits, FITFOCUS is expected to further consolidate its advantages in precision diagnosis and treatment of brain diseases and brain health, as well as in the innovation and transformation of non-invasive neuromodulation technologies.

Regarding this round of financing, the investors stated"Against the backdrop of the industry's rapid development, Yuanming adheres to the investment philosophy of 'insight into industry prospects and deep exploration of value creation,' hoping to propel FITFOCUS to become a benchmark enterprise under the dual support of capital and policy, with 'improving mitochondrial dysfunction' as its differentiated technical approach for brain diseases and a composite innovation model of 'medical-engineering-research.'"